

Dabrafenib Mesylate (GSK-2118436 Mesylate;GSK 2118436B)

Catalog No: tcsc1641



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g



Specifications

CAS No:

1195768-06-9

Formula:

$C_{24}H_{24}F_3N_5O_5S_3$

Pathway:

MAPK/ERK Pathway

Target:

Raf

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 36 mg/mL (58.47 mM)

Alternative Names:

GSK2118436 Mesylate; GSK 2118436B

Observed Molecular Weight:

615.67


Product Description

Dabrafenib (Mesylate) is a novel, potent, and selective **Raf kinase** inhibitor, and inhibits the kinase activity of B-Raf^{V600E} and c-Raf with **IC₅₀** values of 0.6 and 5.0 nM, respectively.

IC₅₀ & Target: IC₅₀: 0.6 nM (BRAF^{V600E}), 5 nM (CRAF)^[4]

In Vitro: Dabrafenib (GSK2118436, 1 μ M) with 0.01 μ M GSK1120212 inhibits more than 90% of cell growth in the NRAS mutant clones. GSK2118436 is sufficient to reduce S6P phosphorylation in A375^[1]. Dabrafenib suppresses the PolyP-mediated vascular barrier permeability, upregulation of inflammatory biomarkers, adhesion/migration of leukocytes, and activation and/or production of nuclear factor- κ B, tumor necrosis factor- α , and interleukin-6^[2]. Dabrafenib inhibits the release of HMGB1 and downregulates HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells^[3].

In Vivo: Dabrafenib-treated females have mostly immature reproductive tracts with no evidence of ovulation, similar to age-matched controls; however, DAB-treated females have keratinized and histologically open vaginas^[5].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!